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Abstract  
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by joint inflammation and 
joint pain. Much of RA treatment is focused on suppressing inflammation, with the idea being that if 
inflammation is controlled other symptoms, such as pain, will disappear.  However, pain is the most 
common complaint of RA patients, is often still present following the resolution of inflammation, and 
can develop prior to the onset of inflammation. Thus, further research is needed to better understand 
RA-associated pain mechanisms. A number of preclinical rodent models commonly used in 
rheumatology research have been developed based on bedside-to-bench and reverse translational 
approaches. These models include collagen-induced arthritis, antigen-induced arthritis, streptococcal 
cell wall-induced arthritis, collagen antibody-induced arthritis, serum transfer from K/BxN transgenic 
mice and tumor necrosis factor (TNF)-transgene mice. They have led to increased understanding of RA 
pathogenesis and have aided the development of successful RA treatments. More recently, these 
models have been used to elucidate the complexities of RA associated pain. Several potentially 
modifiable mechanisms, other than inflammation, have been investigated in these models and may in 
turn lead to more effective treatments. Furthermore, preclinical research can indicate when specific 
treatment strategies may benefit specific patient subgroups or at which disease stage they are best used. 
This review not only highlights RA-associated pain mechanisms, but also suggests the usefulness of 
preclinical animal research based on a bedside-to-bench approach.  
 
 
 
 
 
 
 3 
 
1. Introduction 
Rheumatoid arthritis (RA) is a debilitating systemic disease characterized by joint inflammation 
(edema and synovitis), fatigue and joint pain. If left untreated, the disease leads to bone and cartilage 
destruction and increased mortality. In developed countries RA affects 0.5-1% of the population and is 
approximately 3 times more common in women than men. Joint pain, termed arthralgia, commonly 
develops prior to disease onset [66] and can change in quality and intensity during the course of the day 
and as the disease progresses [22,26,65,70]. The introduction of new disease-modifying antirheumatic 
drugs (DMARDS) has dramatically improved the prognosis of RA patients. More problematic however 
is that a significant proportion of patients fail to report long-term suppression of pain that reflects the 
degree of disease control. Even if treatment with DMARDs reduces pain during the course of 
treatment, a proportion of RA patients are dissatisfied with their pain management and continue to rate 
pain relief as one of their top priorities for improved health and quality of life [6,97,164,170].    
 The etiology of RA is unclear, but genetic and environmental factors are thought to drive 
autoimmune-directed pathological events. Antibodies that recognize endogenous proteins (i.e. 
autoantibodies) in the sera is an underlying characteristic of ~70% of RA cases, and autoantibodies can 
be present for years prior to RA diagnosis [141].  Seropositive RA is associated with an increased risk 
for bone erosion and joint damage [67], while seronegative RA patients often present with higher 
inflammatory activity [130]. Rheumatoid factor (RF) directed against the Fc domain of IgG and anti-
citrullinated protein antibodies (ACPA) that bind proteins where arginine has been converted to 
citrulline (e.g. vimentin, fibrinogen, alpha-enolase) are the most prominent autoantibodies in RA and 
are used for diagnosis. In addition, autoantibodies against cartilage components, such as anti-collagen 
type II (CII) antibodies, and autoantibodies against post-translational modifications other than 
citrullination, such as anti-carbamylated protein antibodies (anti-CarP) have been described in RA 
patients [40,69,82,123,155,164].    
 4 
Autoantibodies exert their actions by directly binding their antigens (i.e. collagen), which can 
result in functional modifications of the antigen. They also form immune complexes (IC, a complex of 
antibodies bound to an antigen) that activate the complement system and Fc receptors (FcRs). 
Interestingly, autoantibodies may be coupled to pathology and pain in the absence of overt joint 
inflammation. Arthralgia and autoantibodies, especially ACPA, are strong predictors of RA 
development and this period before diagnosis is termed ‘pre-RA’ [18,106].  Transfer of ACPA to naive 
mice induce both pain-like behaviour and bone erosion without causing synovitis  [92,180]. ACPA can 
however prolong LPS-induced inflammation and pain-like behaviour, or worsen existing synovitis 
[94]. Thus, multiple “hits” may be necessary for the development of RA. One potential scenario is that 
the presence of certain autoantibodies at the time of a trauma or infection lead to a non-resolving 
immune response and persistent pain.  
The inflammatory events in RA involve both innate and adaptive immunity. The innate immune 
response includes macrophages, and dendritic cells, which produce a cascade of inflammatory 
mediators that attract neutrophils and cells of the adaptive immune system, T and B cells, to the site of 
injury. The environment shaped by this process will ultimately lead to the destruction of the joint. 
Central to RA pathogenesis is the release of proinflammatory cytokines, such as tumor necrosis factor 
(TNF) and interleukins 1, 6, and 17 (IL-1, IL-6, and IL-17). Therapies targeting inflammatory 
processes including conventional DMARDS like methotrexate, and biologic DMARDs, such as 
cytokine blocking anti-TNF therapies (i.e. etanercept and infliximab) and IL-6 signaling inhibition (i.e. 
tocilizumab), are often successful at controlling joint inflammation (reducing swelling and synovitis) 
and limiting joint destruction [176,179]. However, as mentioned, subpopulations of patients  continue 
to report pain as problematic [97,98,170].  An increasing amount of evidence indicates that RA-
associated pain is not solely driven by peripheral inflammatory processes. A number of recent studies 
suggest central pain processing is altered in RA [55,99]. For example, people with RA display 
reductions in pressure and thermal pain-thresholds and increased pain sensitivity over inflamed joints, 
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as well as at remote, non-articular sites [53,139]. Neuropathic pain symptoms have only been 
sporadically tested in RA patients but studies using the painDETECT questionnaire show that a 
subpopulation of RA patients may have a neuropathic component [5,28,56,90,144]. Up to 20% of RA 
patients fulfill the criteria of “likely neuropathic pain” and direct measurements revealed that 33% of 
people with RA who reported neuropathic symptoms displayed clinical evidence of neuropathy [157]. 
The fact that autoantibodies, inflammation, and pain do not always go hand in hand indicates that RA 
pain mechanisms are more complex than simply being driven by inflammation.  Thus, advancing our 
understanding of the relation between RA pathology and persistent joint pain is critical for 
development of improved pain relief strategies. 
Over the past 40 years, a number of arthritis models have been developed in the rheumatology 
field based on common characteristics of RA such as autoimmunity, synovitis, and bone and cartilage 
degradation [13,174]. These models have contributed to the development of several biologic DMARDs 
that are used today [113], such as anti-TNF therapies [84,118,181]. However, when therapies were 
being developed, joint inflammation was the primary consideration and pain was rarely evaluated. 
When evaluating arthritis-associated pain mechanisms, models of inflammatory pain induced by intra-
articular injections of Complete Freund’s Adjuvant (CFA) or carrageenan are frequently used. 
However, these models are based on local activation of the innate immune system and do not include 
aspects of an adaptive immune response. Thus intra-articular injection of CFA or carrageenan may not 
be the best strategy to investigate RA-associated pain mechanisms. The use of different models in RA 
research and pain research has in some ways led to a disconnect between fields. One may argue that it 
is the local innate inflammation that alters neuronal excitability in arthritis and the way of generating 
such a state is not critical. Of course, no single animal model will recapitulate all aspects of human 
pathology but using a number of clinically informed models likely has a greater chance to include 
important aspects of the disease mechanisms that are critical for “chronification” of pain in arthritis. 
Thus, a reverse translational research (i.e. bedside-to-bench) approach using animal models that are 
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based on and informed by the symptoms, mechanisms and characteristics of RA identified in patients is 
of value to identify therapeutic strategies to manage pain.  [1,46]. The following is a brief introduction 
to RA models that have been utilized in pain studies (Table 1). We then highlight pain-related findings 
from these models with an emphasis on cytokines, receptors and ion channels. 
2. Animal Models of RA 
 
2.1 Immunization Models 
Collagen type II (CII) is one of the main extracellular matrix proteins in articular cartilage and 
therefore anti-CII antibodies target the joint. Autoantibodies against CII are found in serum and 
synovial fluid of a subset RA patients [40,69,82,123], including at diagnosis [40,107,123].  Collagen 
induced arthritis (CIA) is the most frequently used experimental model of RA [126]. It is established by 
immunization with CII in complete CFA which leads to production of anti-CII antibodies directed to 
the same major CII epitopes as in RA patients [101]. In mice and rats, polyarthritis develops within 3-4 
weeks after immunization and many important features of human RA are recapitulated, including T- 
and B-cell activation and mononuclear cell infiltration into synovium, joint cavity and periarticular 
structures. Synovial oedema, hyperplasia, and cartilage and bone erosion also occur in CIA [44,145]. 
CIA mice display decreased climbing, locomotion and grooming behaviours [73], thermal 
hypersensitivity [73,83], and mechanical hypersensitivity, which develops prior to inflammation 
[11,12] and lasts for at least 28 days following arthritis-onset [73]. 
Antigen-induced arthritis (AIA) and streptococcal cell wall (SCW) induced arthritis are T-cell 
mediated monoarthritis models commonly used in mice and rats [20,21,78,86,152]. The rodents are 
immunized against the antigen (methylated bovine serum albumin/ovalbumin and SCW, respectively). 
In AIA the antigen is mixed with CFA and inoculated at the base of the tail. The antigen is then 
injected alone into the joint three weeks later. In SCW-induced monoarthritis SCW fragments are 
injected intra-articularly followed by low dose intravenous (i.v.) challenges of SCW (“reactivation”) 
giving rise to flair ups. Both models are characterized by a transition from acute phase with joint 
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swelling and immune cell infiltration to a chronic stage with synovial hyperplasia, cartilage loss and 
bone erosion in the sensitized joint. The joint inflammation is caused by local antigen-specific T-cell 
hyperreactivity and also deposition of immune complex (formations of antibodies bound to the antigen) 
in AIA[12,41]. While pain-like behaviour has been assessed extensively in the AIA model, there are 
only few reports on SCW-arthritis induced pain-like behaviour. Nevertheless, in the AIA model 
mechanical hypersensitivity (up to 8 weeks), thermal hypersensitivity (6 weeks), and altered gait and 
guarding behaviour have been observed in the paw of the inflamed knee joint [15,189]. In the SCW-
arthritis model mechanical hypersensitivity follows the timing of inflammatory flares [25]. 
2.2 Transfer Models 
The presence of anti-CII antibodies in RA patients and mice subjected to CIA and the association 
between these and joint pathology have formed the basis for the collagen antibody-induced arthritis 
(CAIA) model [126,163,169]. A cocktail of anti-CII antibodies (IgG2a and IgG2b) is injected i.v. or 
intraperitoneally (i.p.) and three to five days later lipopolysaccharide (LPS) is injected i.p. to 
synchronize the onset of joint inflammation and increase the incidence and severity of the arthritis 
[126]. The K/BxN model is another transfer model of arthritis that is based on transfer of serum instead 
of antibodies. K/BxN transgenic mice spontaneously develop RA-like pathology [27,91]. Transfer of 
serum from K/BxN mice to naive recipient mice via one or two i.p. injections induces reproducible 
arthritis [75,105]. Anti-glucose-6-phosphate isomerase (GPI) antibodies (IgG1) together with 
inflammatory factors in the serum drives development of the arthritis [27,111]. Both the CAIA and 
K/BXN models develop swelling in small joints of the front and hind paws and sometimes in large 
joints within the first week after induction, with faster onset in the K/BxN model compared to CAIA. 
The degree of pannus formation and erosion of cartilage and bone is dependent on mouse strain and 
sex. Visual signs of joint inflammation resolve 2-4 weeks after induction and there is residual bone 
erosion detectable for several weeks after resolution. Of note, while both models mimic the effector 
phase of an adaptive immune response, T and B-cells per se only play a minor role [126]. In both 
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models development of mechanical hypersensitivity precedes inflammation, is maintained during 
inflammation and persists for several weeks after the resolution of joint inflammation 
[3,10,17,19,29,31,165]. In addition, mice display thermal hypersensitivity [10,11,29,30] and reduced 
locomotor activity [19,150,158,166] 
Although not yet an established model of RA, transfer of ACPA IgG isolated from patients or 
patient B-cell derived murinized monoclonal ACPA to naïve mice leads to mechanical and thermal 
hypersensitivity, decreased locomotor activity and bone erosion in the absence of joint inflammation or 
sickness [92,180]. The pain-like behavior develops within 3-7 days and lasts up to 28 days post 
injection. Thus, transfer of ACPA can be used as a model to investigate “pre-RA” arthralgia and how 
autoantibodies induce joint pain independent of inflammation. 
2.3 Genetic models  
Several strains of transgenic mice overexpressing single or multiple copies of a 3’-modified human 
TNF transgene (TNF-tg) have been developed to investigate the role of TNF in RA pathology [80,100]. 
At 3-4 weeks of age these mice spontaneously develop progressive inflammatory arthritis with ankle 
joint swelling, synovial hyperplasia and immune cell infiltration evident and by 9-10 weeks pannus 
formation, bone and cartilage destruction and fibrosis detectable. The TNF-tg mice display mechanical 
and thermal hypersensitivity by week 6, which is still present at week 10. Tail-flick responses increase 
and motor and mobility are decreased at week 10 [68].  
3. Sex in RA Models  
Preclinical pain research has been criticized for primarily using male rodents despite female humans 
being disproportionality affected by chronic pain. In 2005 Mogil and Chanda found 79% of rodent 
studies published in PAIN over the previous ten years used males only, 8% female only, 9% male and 
female and in 3% sex was unspecified [120]. Mogil recently stated that these percentages were similar 
in 2015 [119].  In fact, recent rodent discoveries have highlighted sex difference in pain-like behaviour 
[108,159,160] and immunity mechanisms [108,121]. In 2014 the NIH created a policy requiring 
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preclinical research to use male and female rodents [38]. Interestingly, Janine Clayton, the director of 
the US National Institutes of Health (NIH) Office of Research on Women’s Health stated that research 
falling under the National Institute of Arthritis and Musculoskeletal and Skin Diseases, such as RA, 
display a better balance in terms of sex in preclinical studies [37]. This prompted us to examine the 
distribution of rodent sex for studies focused on pain-like behaviour in arthritis. We identified 51 
studies using the models described in this review. In nearly 50% of the studies females or male and 
female rodents were used (Table 2). Thus, sex was better balanced compared to the average in the pain 
field described in 2005.  Still, nearly 50% of the studies were conducted in male rodents only. 
Therefore, more female and female/male comparisons in arthritis-pain research are still needed, 
especially considering that RA disproportionately affects females.  
4. Mechanisms 
Here we review RA associated pain mechanisms by focusing on specific factors (i.e. cytokines) that 
have been investigated using the above models (Table 3). Comprehensive reviews of mechanisms 
focusing on particular cell types (i.e. glia) [11] and on RA inflammation and joint destruction can be 
found elsewhere [13,88,113]. 
4.1 Cytokines and Chemokines 
4.1.1 TNF 
TNF blockade reduces pain-like behavior in TNF-tg mice [68] and in male CIA, CAIA, K/BxN 
[11,14,29,73] and female CAIA, SCW and AIA rodents [11,16,25].  Despite minimal effect on joint 
inflammation, TNF inhibition during the inflammatory phase of AIA and CAIA rapidly reverses pain-
like behavior and the effect is maintained in the late “non- inflammatory” stage [11,14].  Similarly, 
etanercept, a soluble TNF decoy receptor, attenuates mechanical hypersensitivity in the K/BxN and 
SCW models, but only during joint inflammation [25,29]. Traditionally the pronociceptive actions of 
TNF have been linked to stimulation of immune cells, chondrocytes and synoviocytes leading to 
production of pain-inducing factors. However, the analgesic effect of TNF inhibitors is evident prior to 
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reduction of inflammation. Preventing activation of the neuronally expressed TNF receptors TNFRI 
[151,156] and possibly TNFRII [14,151] reduces neuronal excitability [73], suggesting that TNF 
contributes to pain signal transmission both directly and indirectly. Interestingly, RA patients treated 
with the TNF antibody infliximab experience pain relief prior to anti-inflammatory effects. These 
effects are associated with a reduction in painful stimuli-induced BOLD signal in pain-perception areas 
of the brain [68]. TNF-tg mice also have altered pain-related brain connectivity and activity, which is 
normalized by infliximab [68]. Thus, peripheral TNF blockade alters pain-related CNS activity in RA. 
In addition, intrathecal injection of etanercept rapidly decreases mechanical hypersensitivity [14] and 
spinal hyperexcitability in male AIA rats [89], suggesting that TNF also regulates pain signaling at the 
level of the spinal cord. Taken together, these data suggest TNF contributes to RA-associated pain by 
directly activating sensory neurons, through inflammatory processes and through spinal TNF signaling.  
4.1.2 IL-1β 
The IL-1 receptor (IL-1R) antagonist anakinra reduces disease activity in a relatively small 
subpopulation of RA patients [112]. Despite an increase of IL-1R expression in DRGs from female rats 
subjected to AIA [38] and periarticular tissues from male CIA rats [149], and the demonstrated direct 
effect of IL-1β directly on sensory neurons [43,52,109], anakinra has a limited effect on pain-like 
behavior. While it decreases thermal hypersensitivity, it does not reduce mechanical hypersensitivity in 
AIA [52,153]. Noteworthy, IL-1β levels are elevated in the cerebrospinal fluid (CSF) of RA patients 
[7,96] and female CIA rats [129], and  IL-1β gene expression is elevated in male K/BxN spinal cords 
[96]. Spinal P2X7 antagonism reduces IL-1β levels, microgliosis and mechanical hypersensitivity [129] 
in CIA female rats suggesting that spinal IL-1β may be microglia dependent. Intrathecal injection of 
IL-1β increases dorsal horn neuronal activity and mechanical hypersensitivity in rats further supporting 
a direct role of spinal IL-1β in pain signaling [142]. Thus, these results not only explain the limited 
efficacy of IL-1β inhibition on RA-associated pain, but also suggest targeting central IL-1β signaling, 
rather than peripheral or systemic IL-1β, may be a more efficacious strategy for pain management.  
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4.1.3 Il-6 
Like in RA patients, IL-6 is elevated in the synovial fluid of male CIA rats [133]. Intra-articular 
injection, and to a lesser extent systemic injection, of IL-6 inhibitors decrease pain-like behavior in 
female AIA rats, without affecting the joint inflammation [127]. Similar to TNF, this suggests a direct 
action of IL-6 on sensory neurons. Interestingly, IL-6 receptors are expressed by DRG neurons and 
satellite glial cells, both of which respond to IL-6 stimulation [49,58]. The role of IL-6 actions on 
satellite glial cells has not been investigated in detail, but sensory neuron-specific deletion of gp130 
(IL-6 signaling transducer) attenuates pain-like behavior and joint inflammation in male and female 
AIA mice [51]. The role of central IL-6 in models of RA-induced pain has not yet been investigated but 
evidence to date indicates that peripheral IL-6 directly affects sensory neurons to drive RA-associated 
pain.  
4.1.4 IL-17 
T-helper 17 cells release the proinflammatory cytokines of the IL-17 family (IL-17A-F), which are 
involved in numerous immune regulatory functions as well as chondrocyte metabolism and 
osteoclastogenesis [9]. IL-17 levels are increased in the joints of male AIA mice and may contribute to 
arthritis pain-like behaviour via neutrophil recruitment and increasing pronociceptive mediators like 
TNF and IL-6 [114,143]. Indeed, IL-17 inhibition decreases neutrophil infiltration into the joint and 
mechanical hypersensitivity [137]. However, IL-17 can also act directly on nociceptors as DRG 
neurons express the IL-17 receptor A-E  [50]. Experiments showing that IL-17 directly increases 
activity of DRG neurons via the IL-17A receptor [50,143] supporting this notion. Furthermore, male 
and female IL-17A knockout mice are protected from AIA-driven mechanical hypersensitivity, but not 
joint inflammation [50]. A central role for IL-17 signaling in models of RA-associated pain has not 
been investigated yet but spinal IL-17A gene expression is elevated in a neuropathic pain model in 
male rats [167] and IL-17 increases astrocyte activity  in vitro [167,188]. Taken together, there are 
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several possible peripheral mechanisms by which IL-17 can contribute to RA-induced pain and it will 
be exciting to see the outcome of IL-17-targeting clinical trials.  
4.1.5 IL-22 
IL-22 is produced by activated NK and T-cells and is involved in the coordination of both the adaptive 
and innate immune system responses. IL-22 expression is increased in the joints of male AIA mice and 
antibody blockade of IL-22 and IL-22 deletion protects mice from AIA-induced mechanical 
hypersensitivity. IL-22-/- AIA mice also show decreased synovitis compared to wild-type AIA mice.  
[138]. The mechanism by which IL-22 contributes to pain is poorly characterized and warrants for 
further studies.  
4.1.6 CXCL1, 2, 5 and 8 
IL-8 (CXCL8) and the murine analogues CXCL1, 2 and 5 are chemokines classically described as 
neutrophil recruitment and activation factors. Along these lines, CXCL1 and 5 levels are elevated in the 
knee and ankles of AIA mice [39,63] and drive neutrophil migration [39,63]. In turn, inhibition of 
CXCR1 and 2, the receptors for CXCL1, 2, 5 and 8, reduces mechanical hypersensitivity in male AIA 
mice [39]. Uncoupled from the neutrophil action, ACPA increases CXCL1 and CXCL2 secretion from 
primary osteoclast cultures.  As ACPA also increases the expression of these chemokines in mouse 
ankle joints [92,180] and CXCR1/2 inhibition decreases both ACPA induced pain-like behaviour and 
bone loss in male mice [92,180] in the absence of other signs of inflammation, CXCL1 and CXCL2 are 
likely to contribute to  RA-associated pain via multiple mechanisms. In support of this notion, CXCL1 
activation of neuronal CXCR2 increases nociceptor excitability and sensitization [48,177,183,187].  A 
central role of CXCL1, 2, 5 or 8 in RA-associated pain signaling has not been investigated, but CXCL1 
is increased in astrocytes and CXCR2 is increased in dorsal horn neurons of male mice subjected to 
nerve injury [190], intraplantar CFA injection [24] or bone cancer pain models [184]. Additionally, 
blocking spinal CXCL1 signaling decreases pain-like behavior in these models. Thus, studies targeting 
spinal CXCL1 signaling are warranted in RA models of pain. Current evidence indicates peripheral 
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CXCL1, 2, 5, and 8 drive RA associated pain via indirect mechanisms like neutrophil recruitment and 
painful bone loss, and by acting directly on nociceptors.    
4.1.7 CX3CL1/Fractalkine 
CX3CL1, known also as fractalkine (FKN), with its receptor CX3CR1 being expressed predominantly 
on microglia, is an important mediator of pain-associated neuron-glia communication in rodents 
[34,102,122,175,186]. Membrane bound FKN is released by the action of the metalloproteases 
ADAM10/17 and cathepsin S (CatS) released by endothelial cells and microglia, respectively 
[36,71,132]. Spinal injection of FKN gives rise to mechanical and thermal hypersensitivity and the 
mechanism behind this effect includes CX3CR1 activation, which triggers intracellular 
phosphorylation of p38 MAPK in the microglia, and stimulates the release of pro-nociceptive cytokines 
[33,35,117,191]. The role of CatS/FKN signaling in chronic pain behavior has been well studied in the 
CIA model. Both early and established mechanical hypersensitivity in CIA are strongly associated with 
CatS/FKN activity in reactive microglia. CatS inhibitor prevents development of pain-like behavior and 
spinal cord hyperexcitability when administered centrally early after immunization, without having any 
effects on joint inflammation [129]. Additionally, continuous i.t treatment with FKN-neutralizing 
antibody attenuated established hypersensitivity concomitantly with dampening the microglia response 
in the spinal cord [32]. This demonstrates that CX3CL1/ CX3CLR1 signaling in the spinal cord is 
important in establishing and maintaining pain-like behavior in this experimental model of arthritis.  
4.2 Toll-like Receptors 
Toll-like receptors (TLR) are activated by endogenous damage-associated molecular patterns (DAMPs) 
such as fragmented extracellular matrix components, HMGB1 and heat-shock proteins. Many DAMPs 
are increased in RA models [31,79,87,116] and TLRs are expressed on a number of cell types, 
including immune cells, glia, chondrocytes, synoviocytes, osteoclasts and sensory neurons [54,79,95]. 
TLR signaling increases nociceptive factors, such TNF and nerve growth factor [79,93], and joint 
inflammation in RA models [79,124].  In male K/BxN mice, spinal gene expression of the TLR4 
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ligands tenascin-c and HSP90 are increased [31] and extranuclear HMGB1 increases in male and 
female CAIA mice [3]. The elevated levels of DAMPS in the spinal cord appears to be linked to pain 
signal transmission as mechanical hypersensitivity is reduced in male TLR4-/- K/BxN mice and spinal 
inhibition of TLR4 signaling during the inflammatory phase but not the late phase of K/BxN arthritis 
reduces mechanical hypersensitivity [31]. Furthermore, blocking spinal HMGB1-TLR4 signaling in 
male and female CAIA mice reverses mechanical hypersensitivity during the inflammatory and late 
phases of the model [4]. Taken together, these results suggest TLR signaling mediates joint 
inflammation and peripheral pain through indirect, and possibly direct, mechanisms.  
4.3 Fc-gamma receptors (FcγR) 
FcγRs are widely expressed by immune cells and they bind the Fc domain of antibodies (IgG) and are 
activated by immune complexes (IC) in order to regulate adaptive immunity. Interestingly, the FcγRI 
(CD64) is expressed in a subpopulation of DRG neurons and co-expressed with nociceptive markers 
including TRPV1, IB4, CGRP and substance P [140]. IgG-IC stimulation of cultured DRG neurons 
increases Ca2+ signaling and excitability [76,140] and intradermal injection of IgG-IC also increases in 
vivo C-fiber excitability and generates mechanical and thermal hypersensitivity [76]. In female AIA 
rats neuronal FcγRI expression is increased and in vitro and in vivo C-fiber excitability is increased in 
response to IgG-IC compared to naïve mice [76]. Furthermore, AIA rats injected with IgG-IC display 
increased pain-like behavior compared to AIA rats alone [76].  DRG neurons in immunized male mice 
also sequester and then release antigen specific IgGs that are produced by B-cells [64]. Thus, FcγRs 
and autoantibodies in IC formation provide a new link between the adaptive immune system and 
activation of sensory fibers innervating the joint that may play important roles in modulation of RA-
associated pain. 
4.4 Ion Channels 
4.4.1 Calcium Channels 
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Alpha-2 delta-1 (α2δ1), an auxiliary subunit of voltage-gated Ca2+ channels, is upregulated in DRG of 
neuropathic, but not usually inflammatory, pain models [11]. However, α2δ1 protein levels are elevated 
in DRG neurons of male CAIA mice, [165]. Gabapentin and pregabalin bind to α2δ subunits (1 and 2) 
and have been found to reduce calcium currents via an effect on trafficking of voltage-dependent 
calcium channels in the CNS [45]. Gabapentin and pregabalin also seem to be effective analgesic drugs 
in models of neuropathic pain, but also in some models of inflammatory pain [104,125,135,162]. 
Additionally, gabapentin reverses mechanical hypersensitivity in both the inflammatory and late phases 
of male K/BxN [29] and CAIA [10] mice. These findings demonstrate an importance of the α2δ1 
subunit in arthritis-induced pain behaviour. Additionally, inhibition of store operated Ca2+ channels 
with YM-58483 prevents and reverses CIA-induced pain-like behavior in male mice [57]. In a 
combination of the AIA and CIA models, nociceptor expression of MVIIA, which blocks the voltage 
gated calcium 2.2 channel, reduces abnormal weight bearing, but also increased joint destruction [8]. 
Taken together, these findings indicate that modulation of calcium channel activity is a potential target 
for arthritis pain management.  
4.4.2 TRPV1 
TRPV1 is a nonselective cation channel expressed by nociceptors that is activated by protons, heat and 
endogenous lipids. It has been investigated as a target for inflammatory pain management including 
arthritis [161]. Pretreating animals with resiniferatoxin in order to desensitize TRPV1 and destroy 
nerve terminals prior to K/BxN serum transfer in male and female mice decreases mechanical 
hypersensitivity. Neutralization of OxPAPC, an endogenous oxidized phospholipid recently identified 
as a TRPV1 and TRPA1 agonist, reduces mechanical and thermal hypersensitivity in male CIA rats 
[131].  However, TRPV1 inactivation increases protease activity, joint swelling and bone erosion [17], 
which is potentially coupled to TRPV1 expression on synoviocytes [85,172], osteoclasts [147] and 
osteoblast-like cells [2]. These findings suggest several potentially opposing roles of TRPV1 in RA, 
thus inhibition could have unintended consequences.    
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4.4.3 Acid Sensing Ion Channels 
Acid sensing ion channels (ASIC) are activated by decreased pH and endogenous lipids [110]. AISC3 
is expressed by sensory fibers innervating the joint [72], synoviocytes [61] and osteoclasts [74]. 
Interestingly, ASIC3-/- mice are protected from CAIA-induced pain-like behavior during the 
inflammatory phase, but paw inflammation, bone erosion and joint destruction increase when compared 
to wild-type mice with CAIA  [158]. While neuronal ASIC3 is linked to pain generation, it may have a 
protective regulatory role in synoviocytes [61] or osteoclasts.   
4.5 Nerve Injury and Neuropathic Pain Markers 
ATF3 and GAP43 are commonly used as markers of nerve injury. ATF3 expression in DRG neurons is 
elevated in male mice subjected to CIA [73], K/BxN [29] and CAIA [165]. GAP43 is elevated in DRG 
neurons during the inflammatory phase and late phase of the CAIA model [165] and GAP43 skin fiber 
density, a sign of peripheral neuropathy, is increased in female AIA rats, even in the absence on 
inflammation [77]. These findings, along with α2δ1 findings discussed above, suggest that 
inflammatory processes in conjunction with bone and/or cartilage remodeling in the joint introduce 
changes in the local environment that induces stress or is damaging to sensory neurons. 
5. Future Directions and Conclusions 
While chronic pain is an area of intense study, the translation of discoveries made in animal 
models into novel pain therapies for humans has been challenging. The long-term consequences of 
inflammatory processes in the joint and how they are coupled to maladaptive mechanisms in the 
peripheral and central nervous system leading to persistent joint pain is still poorly understood. 
Importantly, animal models of RA have proven useful in understanding disease pathophysiology and 
the development of disease modifying agents. More frequent utilization of these models in pain 
research may guide us to new discoveries.  
Recent advances in the development of new DMARDs may provide new opportunities also 
from a pain perspective. For example janus kinase (JAK) inhibitors, like tofacitinib and baricitinib are 
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newly approved DMARDs that were developed with the aid of preclinical research [23,115,185] and 
reported to improve RA associated pain in patients [42,56,60], even before disease modification in one 
study [171].  Exploring the role of JAK/STAT signaling in arthritis-induced pain represents an exciting 
area of research, especially given earlier work pointing to involvement of spinal JAK/STAT in nerve 
injury induced pain [47]. Another emerging strategy is use of bispecific antibodies that target multiple 
cytokines, with the idea being that targeting a single cytokine may be insufficient due to over lapping 
functions of multiple cytokines. Bispecific antibodies against IL-17A and IL-17F, IL-17A and TNF, 
and IL-1β and IL-17 are under development and in clinical trials for RA [9]. IL-1β and IL-17 bispecific 
antibodies decrease joint inflammation, proinflammatory cytokine levels and bone erosion in the CIA 
model [148,178,182], but the effect on pain has not been investigated.  Blocking the effect of multiple 
cytokines may provide additative or synergistic effect in terms of pain relief, especially if targeting 
factors that are key components of the innate and adaptive immune system at the same time. 
Current guidelines recommend using non-steroidal anti-inflammatory drugs (NSAIDs) to 
manage RA pain. Studies utilizing the CAIA [10], K/BxN [29,134], AIA (refs) and CIA [73] models 
show that NSAIDs and inhibition of certain cytokines decrease pain-like behavior only during active 
disease. However, both preclinical RA models and clinical research have suggested a neuropathic 
component to RA-associated pain. Thus, the use of drugs that are currently used to treat neuropathic 
pain may be useful to treat RA-associated pain in the absence of inflammation. Use of RA models with 
distinct characteristics can likely help elucidate when one treatment may be beneficial over another. 
In addition to pharmacological strategies, the European League Against Rheumatism (EULAR) 
guidelines for RA pain management with non-pharmacological interventions were recently published. 
They recommended physical activity/exercise regimes and diet/weight management to help manage 
RA pain [59]. The effects of physical activity and exercise are increasingly being characterized in a 
number of pain models [62,136,146,154], but not yet RA-associated pain. Similarly, diet modulation of 
pain is a growing preclinical research area, partially due to the effect of diet on inflammation. High fat 
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diets increase mechanical and thermal hypersensitivity in naïve mice [173], and in mice receiving paw 
[173], or knee intra-articular knee CFA injections [103]. CIA mice fed a high-fat diet have increased 
signs of inflammation and an earlier arthritis onset [81,168], but the effect on pain was not been 
investigated. Thus, diet and exercise modulation of pain in preclinical RA models are areas ready for 
reverse translational research to better understand the mechanisms behind these interventions. 
In conclusion, pain relief following DMARD introduction is in part most likely attributable to 
suppression of joint inflammation. Still, pain remains problematic in subpopulations of RA patients.  
Several of the animal models of RA described in this review recapitulate this feature, thus they have the 
potential to aid in advancing our understanding of mechanisms that underpin the “remaining pain”. As 
the complexity of RA pathology is being unraveled, exploring the role of factors that contribute to RA 
pathology, but have not yet been investigated from a pain perspective, could open doors to more 
effective pain-relieving strategies.  Based on current data generated with RA models in pain studies, 
one may predict that targeting certain factors, pathways or mechanisms will be more effective at 
controlling pain than targeting others. Moving forward, more studies should include male and female 
rodents to avoid potential confounding factors and possibly identify exciting sex-dependent differences. 
Continued use of preclinical RA models based on bedside-to-bench principals will ultimately continue 
to delineate complex pain mechanisms and aid the development and deployment of novel and existing 
therapies, not only for pain in RA but also pain in other conditions.  
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Table 1: Model overview 
 
 CIA AIA SCW CAIA K/BxN ACPA TNF-tg 
Trigger CII/ 
adjuvant 
mBSA/ adjuvant Bacterial cell 
wall 
Anti-CII Ab Serum/ 
Anti-GPI Ab 
ACPA hTNF over-
expression 
Poly/mono Poly Mono Mono Poly Poly Poly Poly 
Similarities to 
Human RA 
Adaptive 
immune system 
activation 
against 
endogenous 
joint epitopes 
Inflm 
Immune cell 
infiltration 
Joint destruction 
Adaptive 
immune system 
activation 
against 
exogenous 
epitope 
 Inflm 
Immune cell 
infiltration 
Joint destruction 
Inflm 
Immune cell 
infiltration 
-Joint 
destruction 
Recurrent  flares 
Joint specific ab 
Inflm  
Immune cell 
infiltration 
Joint destruction 
Immune cell 
infiltration 
Three phases of 
pain 
Inflm 
Immune cell 
infiltration 
Joint destruction 
Three phases of 
pain 
Ab mediated 
processes 
Bone erosion 
 
Inflm 
Immune cell 
infiltration 
Joint destruction 
Pain Behavior Mech 
Spont 
Loco 
Mech 
Thermal 
Gait 
Guarding 
 
Mech Mech 
Therm 
Loco 
Mech 
Therm 
Loco 
Mech 
Therm 
Loco 
 
Mech 
Therm 
Tail flick 
 
Abbreviations: Poly, poly arthritis; mono, monoarthritis; inflm, joint inflammation; ab, antibody; mech, mechanical hypersensitivity; therm, thermal 
hypersensitivity; loco, decreased locomotive activity 
  
	
	
	
	
	
Table 2: Sex Distribution by Model in Preclinical RA Pain Studies 
Model # of Studies Male Female Male and 
female 
Unspecified 
CIA [7,12,37,62,73,81,139,140,142] 10 5 4 1 0 
AIA [19–21,54–
57,84,85,97,121,148,149,154,160,164–
166,188,202] 
20 6 10 3 1 
SCW [30] 1 0 1 0 0 
CAIA [3,14,15,114,145,161,170,177] 8 6 0 2 0 
K/BxN [22,34,36,76,77,104,116,145,178] 9 7 0 1 1 
ACPA [193] 1 1 0 0 0 
TNF-tg [74] 1 0 0 0 1 
CIA/AIA [9,11] 1 0 0 0 1 
Total 51 25 15 7 4 
% total 100% 49% 30% 13 % 8% 
 
  
	
	
	
	
	
Table 3: Factors Implicated in Peripheral and Central Pain Mechanisms 
 CIA CAIA AIA K/BxN TNF-tg ACPA SCW 
Peripheral 
Factors 
TNF 
IL-6 
NGF 
SOC 
Antibodies 
Nerve-
injury 
TNF 
IL-6 
α2δ1 
Antibodies 
Nerve-
injury 
PGs 
ASIC3 
TNF 
IL-6 
IL-17 
CXCL1 
CXCL5 
Antibodies 
TNF 
α2δ1 
TRPV1 
Antibodies 
Nerve-
injury 
PGs 
TNF CXCL1 
CXCL2 
Antibodies 
Antibodies 
TNF 
Central 
Factors 
IL-1β 
 
TNF 
TLR4 
TNF 
IL-17? 
TLR4 TNF TBD TBD 
 
 TBD, to be determined  
 
